It depends on the exact terms of the tacit agreement between NVS and MNTA that Bernstein refers to. Assuming that such an agreement exists, we still don’t know to what extent an un-launch of the Amphastar/WPI generic would raise MNTA’s Lovenox take relative to what MNTA was getting under the pre-launch “hybrid” formula.